title: Early channel transurethral resection of the prostate for patients with urinary retention after brachytherapy.
abstract: OBJECTIVE
  It is recommended that transurethral resection of the prostate (TURP) after brachytherapy should not be performed at an early stage after implantation. Herein we report our experiences and the results of channel TURP (cTURP) within six months post-implant for patients with refractory urinary retention.
  
  
  METHODS
  One hundred and ninety patients with localized prostate cancer of clinical stages T1c to T2c were treated by brachytherapy as monotherapy at our institution from February 2009 to July 2013. Nine patients who developed refractory urinary retention and underwent cTURP within six months after brachytherapy were retrospectively reviewed and analyzed.
  
  
  RESULTS
  The median interval between prostate brachytherapy and cTURP was three months (range 1.5 to 5.0 months). There were no intraoperative or postoperative complications and no incontinence resulting from the surgery. All urinary retention was relieved per the American Brachytherapy Society urinary symptom score. With a mean follow-up time of 16 months (range 6 to 26 months) after cTURP, no patient experienced biochemical recurrence. The mean serum prostate-specific antigen (PSA) of the patients who underwent cTURP was 0.42 ng/ml (range 0.08 to 0.83 ng/ml) at the end of their follow-up.
  
  
  CONCLUSIONS
  Early cTURP was found to be safe and effective in relieving urinary retention after brachytherapy and could be performed without compromising its therapeutic efficacy.
authors.affiliation: Department of Urology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou 310016, China; Department of Urology, the First People's Hospital of Xiaoshan, Hangzhou 311200, China.
authors.forename: You-yun
authors.initials: YY
authors.lastname: Zhang
authors.forename: Zhi-gen
authors.initials: ZG
authors.lastname: Zhang
authors.forename: Yan-lan
authors.initials: YL
authors.lastname: Yu
authors.forename: Yi-cheng
authors.initials: YC
authors.lastname: Chen
authors.forename: Kang-xin
authors.initials: KX
authors.lastname: Ni
authors.forename: Ming-chao
authors.initials: MC
authors.lastname: Wang
authors.forename: Wei-ping
authors.initials: WP
authors.lastname: Zhao
authors.forename: Faisal
authors.initials: F
authors.lastname: Rehman
authors.forename: Shaw P
authors.initials: SP
authors.lastname: Wan
authors.forename: Gong-hui
authors.initials: GH
authors.lastname: Li
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001918:Brachytherapy / Q000009:adverse effects*; D006801:Humans; D007610:Kallikreins / Q000097:blood; D008297:Male; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000532:radiotherapy* / Q000601:surgery*; D012189:Retrospective Studies; D013997:Time Factors; D020728:Transurethral Resection of Prostate / Q000379:methods*; D016055:Urinary Retention / Q000209:etiology* / Q000601:surgery*
chemical_list: C549870:KLK3 protein, human; D007610:Kallikreins; D017430:Prostate-Specific Antigen
keywords: Brachytherapy; Prostate cancer; Transurethral resection of the prostate (TURP)
references.citation: Eur Urol. 2002 Apr;41(4):427-33
references.pmid: 12074815
references.citation: CA Cancer J Clin. 2001 Jan-Feb;51(1):15-36
references.pmid: 11577478
references.citation: J Clin Oncol. 2004 Jun 1;22(11):2141-9
references.pmid: 15169800
references.citation: J Urol. 2002 Feb;167(2 Pt 2):981-3; discussion 984
references.pmid: 11905928
references.citation: Radiat Oncol Investig. 1999;7(1):30-5
references.pmid: 10030621
references.citation: J Endourol. 2005 Jun;19(5):546-9
references.pmid: 15989442
references.citation: Urology. 1991 Dec;38(6):526-8
references.pmid: 1746080
references.citation: Int J Urol. 2006 Apr;13(4):368-72
references.pmid: 16734852
references.citation: Urology. 2003 Jul;62(1):79-85
references.pmid: 12837427
references.citation: Prog Urol. 2000 Feb;10(1):3-13
references.pmid: 10785912
references.citation: J Urol. 2004 Jul;172(1):108-11
references.pmid: 15201748
references.citation: Semin Urol Oncol. 2000 May;18(2):160-5
references.pmid: 10875459
references.citation: Int J Radiat Oncol Biol Phys. 2003 Jun 1;56(2):454-61
references.pmid: 12738320
references.citation: BJU Int. 2005 Jul;96(1):43-7
references.pmid: 15963118
references.citation: Int J Radiat Oncol Biol Phys. 1995 May 15;32(2):465-71
references.pmid: 7751187
references.citation: Br J Urol. 1994 Sep;74(3):333-6
references.pmid: 7524997
references.citation: BJU Int. 2003 Apr;91(6):477-81
references.pmid: 12656897
references.citation: J Urol. 2005 Mar;173(3):808-12
references.pmid: 15711274
references.citation: Radiother Oncol. 2004 Apr;71(1):29-33
references.pmid: 15066293
references.citation: Int J Radiat Oncol Biol Phys. 1999 Feb 1;43(3):565-70
references.pmid: 10078638
references.citation: CA Cancer J Clin. 2013 Jan;63(1):11-30
references.pmid: 23335087